KalVista Pharmaceuticals, Inc. (KALV)
NASDAQ: KALV · Real-Time Price · USD
16.43
+0.03 (0.18%)
Dec 5, 2025, 4:00 PM EST - Market closed
KalVista Pharmaceuticals Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for KalVista Pharmaceuticals stock have an average target of 26.43, with a low estimate of 20 and a high estimate of 30. The average target predicts an increase of 60.86% from the current stock price of 16.43.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for KalVista Pharmaceuticals stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Buy | 4 | 4 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $28 | Strong Buy | Reiterates | $28 | +70.42% | Dec 4, 2025 |
| Citizens | Citizens | Buy Maintains $29 → $28 | Buy | Maintains | $29 → $28 | +70.42% | Nov 11, 2025 |
| Needham | Needham | Strong Buy Reiterates $28 | Strong Buy | Reiterates | $28 | +70.42% | Sep 12, 2025 |
| JMP Securities | JMP Securities | Buy Maintains $27 → $28 | Buy | Maintains | $27 → $28 | +70.42% | Sep 12, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $27 | Strong Buy | Reiterates | $27 | +64.33% | Jul 11, 2025 |
Financial Forecast
Revenue This Year
60.78M
Revenue Next Year
184.86M
from 60.78M
Increased by 204.16%
EPS This Year
-3.09
from -3.69
EPS Next Year
-1.12
from -3.09
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 104.7M | 262.0M | |||
| Avg | 60.8M | 184.9M | |||
| Low | 13.1M | 99.6M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | 331.0% | |||
| Avg | - | 204.2% | |||
| Low | - | 64.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -2.52 | -0.11 | |||
| Avg | -3.09 | -1.12 | |||
| Low | -3.53 | -2.74 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.